Article

Multi-omics investigation of the resistance mechanisms of Pomalidomide in Multiple Myeloma

2023-07-13

Abstract excerpt

<h4>Background: </h4> Despite significant therapeutic advances over the last decade, Multiple myeloma remains an incurable disease. Pomalidomide is a second-generation Immunomodulatory drug that is commonly used to treat patients with relapsed/refractory multiple myeloma. However, approximately half of the patients exhibit resistance to pomalidomide treatment. While previous studies have identified Cereblon as a p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bcb1924a-f263-576a-b35c-d45dc509eafe
DOI: 10.21203/rs.3.rs-3148217/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multi-omics investigation of the resistance mechanisms of Pomalidomide in Multiple MyelomaDOI 10.21203/rs.3.rs-3148217/v1Read

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trialSemantic proximity Read

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaSemantic proximity Read

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read

A novel ferroptosis-related gene signature for predicting prognosis in multiple myelomaSemantic proximity Read

Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic OpportunitiesSemantic proximity Read

Identification of candidate therapeutics and signaling pathways for multiple myelomaSemantic proximity Read

Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myelomaSemantic proximity Read

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Semantic proximity Read

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read